Cipla

Why is Cipla Ltd. falling/rising?

As of 21-Jun, Cipla Ltd. is facing a decline in its stock price, currently at 1,353.85, due to poor financial performance, including negative results for two consecutive quarters and a significant drop in net sales. The stock has underperformed compared to the benchmark Sensex, with a year-to-date decline of -10.39% and concerns over its high valuation amidst declining profits.

As of 21-Jun, Cipla Ltd. is experiencing a decline in its stock price, currently at 1,353.85, reflecting a change of -1.95 (-0.14%). This downward movement can be attributed to several factors highlighted in the recent performance data. Over the past week, the stock has underperformed significantly, with a decline of -2.52%, while the benchmark Sensex has risen by +1.69%. <BR><BR>In the last month, Cipla's stock has decreased by -3.97%, contrasting with a +2.13% increase in the Sensex. Year-to-date, the stock has fallen by -10.39%, which is slightly worse than the Sensex's decline of -9.88%. Additionally, the stock has shown a negative performance over the past year, with a return of -8.72%, while its profits have decreased by -22.5%.<BR><BR>The company's financial health also raises concerns, as it has reported negative results for the last two consecutive quarters, with a significant fall in net sales of -7.54%. The operating profit growth over the last five years has been modest at an annual rate of 7.97%, indicating poor long-term growth prospects. Furthermore, the return on capital employed (ROCE) is at its lowest at 15.85%, and the net sales for the last quarter were the lowest recorded at Rs 6,541.20 cr.<BR><BR>Despite having a net-debt-free status and high institutional holdings at 54.53%, which typically suggests a level of confidence from more sophisticated investors, the overall performance metrics indicate that the stock is trading at a premium compared to its peers, with a price-to-book value of 3.2. This expensive valuation, combined with declining profits and sales, contributes to the stock's current downward trajectory.

Which are the latest news on Cipla?

How big is Cipla?

As of 10th June, Cipla Ltd. has a market capitalization of 111,652.00 Cr, with recent net sales of 28,162.59 Cr and a net profit of 3,879.23 Cr.

As of 10th June, Cipla Ltd. has a market capitalization of 111,652.00 Cr and is classified as a Large Cap company.<BR><BR>For the latest four quarters, Cipla reported Net Sales of 28,162.59 Cr and a Net Profit of 3,879.23 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, with Shareholder's Funds amounting to 34,431.95 Cr and Total Assets of 41,594.96 Cr.

Who are in the management team of Cipla?

The management team of Cipla includes key members such as Y K Hamied (Chairman), Umang Vohra (Managing Director & Global CEO), and several independent directors like Ashok Sinha and Peter Mugyenyi, who collectively guide the company's strategy and operations.

The management team of Cipla includes the following key members:<BR><BR>1. **Y K Hamied** - Chairman (Non-Executive)<BR>2. **M K Hamied** - Vice Chairman<BR>3. **S Radhakrishnan** - Non-Executive & Non-Independent Director<BR>4. **Ashok Sinha** - Non-Executive & Independent Director<BR>5. **Peter Mugyenyi** - Non-Executive & Independent Director<BR>6. **Adil Zainulbhai** - Non-Executive & Independent Director<BR>7. **Punita Lal** - Non-Executive & Independent Director<BR>8. **Samina Hamied** - Executive Vice Chairperson<BR>9. **Umang Vohra** - Managing Director & Global CEO<BR>10. **Rajendra Chopra** - Company Secretary & Compliance Officer<BR>11. **Robert A Stewart** - Independent Director<BR>12. **P R Ramesh** - Independent Director<BR>13. **Mandar Purushottam Vaidya** - Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategy and operations.

Who are the peers of the Cipla?

Cipla's peers include Sun Pharma, Divi's Lab, Torrent Pharma, Zydus Lifesciences, Dr Reddy's Labs, Lupin, Mankind Pharma, Aurobindo Pharma, Laurus Labs, and Biocon. Cipla has below-average growth and the lowest 1-year return at -8.98% among its peers, while Torrent Pharma leads with a 1-year return of 42.91%.

Peers: Cipla's peers include Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Zydus Lifesci., Dr Reddy's Labs, Lupin, Mankind Pharma, Aurobindo Pharma, Laurus Labs, and Biocon.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Zydus Lifesci., Dr Reddy's Labs, Lupin, Mankind Pharma, Laurus Labs, and the rest. Below Average growth is noted for Cipla, Divi's Lab., Aurobindo Pharma, and Laurus Labs, while Excellent growth is seen at Sun Pharma.Inds., Zydus Lifesci., Lupin, and Mankind Pharma. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Zydus Lifesci., Dr Reddy's Labs, Cipla, Aurobindo Pharma, and the rest.<BR><BR>Return Snapshot: Torrent Pharma has the highest 1-year return at 42.91%, while Cipla has the lowest at -8.98%. Cipla's 1-year return is significantly lower than the average of its peers. Additionally, Cipla and Aurobindo Pharma are among the peers with negative six-month returns.

What does Cipla do?

Cipla Limited is a prominent Indian pharmaceutical company that manufactures and markets a variety of branded and generic drugs and Active Pharmaceutical Ingredients (APIs). As of March 2026, it reported net sales of ₹6,541 Cr and a net profit of ₹555 Cr, with a market capitalization of ₹111,652 Cr.

Overview: <BR>Cipla Limited is a leading pharmaceutical company in India, engaged in the manufacturing, developing, and marketing of a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs) within the Pharmaceuticals & Biotechnology industry.<BR><BR>History: <BR>Cipla was incorporated in an unspecified year and has maintained its status as a prominent player in the pharmaceutical sector. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 6,541 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 555 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 111,652 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 27.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.94% <BR>Debt-Equity: -0.24 <BR>Return on Equity: 11.87% <BR>Price to Book: 3.23<BR><BR>Contact Details: <BR>Address: Cipla House Peninsula Buss Par, Ganpatrao Kadam Mg Lower Parel Mumbai Maharashtra : 400013 <BR>Tel: 91-22-24826000 <BR>Email: cosecretary@cipla.com <BR>Website: http://www.cipla.com

Are Cipla Ltd. latest results good or bad?

Cipla Ltd.'s latest Q4 FY26 results are disappointing, with a 54.61% decline in net profit and a 2.80% drop in net sales, marking the lowest quarterly revenue in a year. The company faces significant operational challenges, leading to a cautious outlook.

Cipla Ltd.'s latest results for Q4 FY26 indicate a challenging performance. The company reported a net profit of ₹554.64 crore, which represents a significant decline of 54.61% year-on-year. Additionally, net sales decreased by 2.80% to ₹6,541.20 crore, marking the lowest quarterly revenue in the past four quarters. Operating margins also contracted sharply to 14.77%, down 853 basis points from the previous year, indicating severe margin compression.<BR><BR>These results reflect broader operational challenges, including rising costs and demand headwinds in key markets. The stock has underperformed significantly, down 12.66% over the past year, while the pharmaceutical sector as a whole has seen a positive return. Overall, the financial performance suggests a negative trend, and the outlook remains cautious until there are signs of recovery in margins and sales growth.

Should I buy, sell or hold Cipla Ltd.?

Is Cipla technically bullish or bearish?

As of December 1, 2025, Cipla's technical trend has shifted to sideways, with mixed indicators showing a mildly bearish MACD, bullish weekly RSI, and conflicting signals from moving averages and Bollinger Bands, indicating a lack of clear direction.

As of 1 December 2025, the technical trend for Cipla has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed indicators influencing the outlook. The MACD is mildly bearish on both the weekly and monthly time frames, while the RSI shows bullish momentum on the weekly but no signal on the monthly. Moving averages indicate a mildly bullish trend on the daily, contrasting with the bearish signals from Bollinger Bands and KST on the weekly. Dow Theory reflects a mildly bearish stance on the weekly and no trend on the monthly. Overall, the mixed signals suggest a lack of clear direction, reinforcing the sideways trend.

How has been the historical performance of Cipla?

Cipla has demonstrated strong financial growth, with net sales increasing from 19,159.59 Cr in Mar'21 to 27,547.62 Cr in Mar'25, and profit after tax rising from 1,546.98 Cr to 5,291.05 Cr during the same period. Key metrics such as operating profit and earnings per share also showed significant improvement, reflecting robust profitability and operational efficiency.

Answer:<BR>Cipla has shown a consistent growth trajectory in its financial performance over the years, with net sales increasing from 19,159.59 Cr in Mar'21 to 27,547.62 Cr in Mar'25. The total operating income followed a similar upward trend, reaching 27,547.62 Cr in Mar'25 from 19,159.59 Cr in Mar'21. The operating profit (PBDIT) also saw significant growth, climbing to 7,989.77 Cr in Mar'25 from 3,550.19 Cr in Mar'20. Profit before tax rose to 6,820.81 Cr in Mar'25, up from 2,178.18 Cr in Mar'20, while profit after tax reached 5,291.05 Cr in Mar'25, compared to 1,546.98 Cr in Mar'20. The earnings per share (EPS) improved markedly, standing at 65.29 in Mar'25, up from 19.18 in Mar'20. <BR><BR>On the balance sheet side, total assets increased from 23,422.79 Cr in Mar'20 to 36,742.17 Cr in Mar'25, with total liabilities also rising from 23,422.79 Cr to 36,742.17 Cr during the same period. Shareholder's funds grew from 15,763.00 Cr in Mar'20 to 31,193.45 Cr in Mar'25, indicating a strengthening equity position. The cash flow from operating activities improved to 5,004.00 Cr in Mar'25 from 3,068.00 Cr in Mar'20, while net cash inflow turned positive at 30.00 Cr in Mar'25, contrasting with negative outflows in previous years. Overall, Cipla's financial metrics reflect a robust growth pattern and improved profitability over the analyzed period. <BR><BR>Breakdown:<BR>Cipla's financial performance has demonstrated a strong upward trend across multiple key metrics. Net sales surged from 19,159.59 Cr in Mar'21 to 27,547.62 Cr in Mar'25, while total operating income mirrored this growth, reaching the same figure in Mar'25. Operating profit (PBDIT) rose significantly from 3,550.19 Cr in Mar'20 to 7,989.77 Cr in Mar'25, showcasing improved operational efficiency. Profit before tax increased from 2,178.18 Cr in Mar'20 to 6,820.81 Cr in Mar'25, and profit after tax followed suit, climbing to 5,291.05 Cr from 1,546.98 Cr in Mar'20. The earnings per share (EPS) also saw a remarkable rise, reaching 65.29 in Mar'25, up from 19.18 in Mar'20. <BR><BR>On the balance sheet, total assets grew from 23,422.79 Cr in Mar'20 to 36,742.17 Cr in Mar'25, with total liabilities increasing in tandem. Shareholder's funds strengthened significantly, rising from 15,763.00 Cr to 31,193.45 Cr over the same period. Cash flow from operating activities improved to 5,004.00 Cr in Mar'25, compared to 3,068.00 Cr in Mar'20, and net cash inflow turned positive at 30.00 Cr in Mar'25, contrasting with negative figures in prior years. This overall performance indicates a solid growth trajectory and enhanced profitability for Cipla.

Is Cipla overvalued or undervalued?

As of May 9, 2025, Cipla is considered undervalued with an attractive valuation grade, a PE Ratio of 22.99, and favorable comparisons to peers like Sun Pharma and Divi's Lab, despite recent stock performance lagging behind the Sensex, while showing strong growth potential with a 54.92% return over three years.

As of 9 May 2025, Cipla's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE Ratio of 22.99, an EV to EBITDA of 15.93, and a PEG Ratio of 0.97, which suggests that the stock is priced favorably relative to its growth potential.<BR><BR>In comparison to its peers, Cipla's valuation appears more appealing, especially when contrasted with Sun Pharma's PE Ratio of 35.25 and Divi's Lab's significantly high PE Ratio of 79.33. Additionally, Dr. Reddy's Labs, which is also rated attractive, has a lower PE Ratio of 19.49, further supporting the notion that Cipla is undervalued in its sector. While Cipla's recent stock performance has lagged behind the Sensex on a year-to-date basis, its strong return over three years at 54.92% reinforces its potential for growth.

Who are the top shareholders of the Cipla?

The top shareholders of Cipla include promoters, with Yusuf Khwaja Hameid holding 18.68%, institutional investors with mutual funds at 20.51% and foreign institutional investors at 26.28%, and individual shareholders who collectively own 14.13%. The largest public shareholder is the HDFC Large and Mid Cap Fund, holding 5.13%.

The top shareholders of Cipla include a mix of promoters, institutional investors, and individual shareholders. The majority shareholders are the promoters, with Yusuf Khwaja Hameid being the promoter with the highest holding at 18.68%. <BR><BR>In terms of institutional investments, mutual funds hold 20.51% of the shares through 42 schemes, while foreign institutional investors (FIIs) hold 26.28% through 980 different entities. The highest public shareholder is the HDFC Large and Mid Cap Fund, which holds 5.13%. Additionally, individual investors collectively hold 14.13% of the company's shares.

When is the next results date for Cipla?

No Upcoming Board Meetings

What is the bonus history of the Cipla?

Cipla's most recent bonus issue occurred on April 24, 2006, when the company announced a 3:2 bonus, granting shareholders three shares for every two held, with a record date of April 25, 2006.

Cipla has a bonus history that includes a notable issuance on April 24, 2006. During this event, the company announced a 3:2 bonus issue, which means that for every two shares held, shareholders received three shares. The record date for this bonus was April 25, 2006. This was the latest bonus action recorded for Cipla. If you have any more questions about the company or its financials, feel free to ask!

Has Cipla declared dividend?

Cipla Ltd. has declared a 650% dividend, with an ex-date of June 27, 2025. The company has shown strong total returns over various periods, including a 134.92% total return over the past 5 years.

Cipla Ltd. has declared a 650% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 650%<BR>- Ex-date: 27 Jun 25<BR><BR>Dividend Yield: 0.87%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Cipla experienced a price return of 1.37%, with no dividend return, resulting in a total return of 1.37%.<BR><BR>Over the past year, the price return was 1.39%, with a dividend return of 0.85%, leading to a total return of 2.24%.<BR><BR>In the 2-year period, Cipla saw a significant price return of 54.06% and a dividend return of 2.13%, culminating in a total return of 56.19%.<BR><BR>For the 3-year period, the price return was 53.43% with a dividend return of 2.89%, resulting in a total return of 56.32%.<BR><BR>In the last 4 years, the company achieved a price return of 58.24% and a dividend return of 3.27%, leading to a total return of 61.51%.<BR><BR>Over the past 5 years, Cipla reported a remarkable price return of 130.04% along with a dividend return of 4.88%, resulting in a total return of 134.92%.<BR><BR>Overall, Cipla has declared a substantial dividend and has shown strong total returns over various periods, indicating a positive performance trend for the company.